这家临床阶段制药公司在招股说明书补充文件中透露,它正在增加根据与A.G.P./Alliance Global Partners和Curvature Securities LLC签订的修订和重述销售协议可能提供和出售的股份数量。这笔1亿美元的融资是在已根据先前招股说明书出售的总销售价格约为6347万美元的股份之外的额外融资。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.